CPO 301
Alternative Names: CPO-301; SYS-6010Latest Information Update: 06 Sep 2023
At a glance
- Originator Conjupro Biotherapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Jun 2023 US FDA approves IND application for CPO 301 in Solid tumours (Late-staged diseases, Metastatic diseases, Second-line therapy or greator), prior to June 2023 (Conjupro Biotherapeutic pipeline, July 2023)
- 06 Jun 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05948865)